CME Presentations




  • Virginia Kaklamani, MD, DSc

    Virginia Kaklamani, MD, DSc

    Virginia Kaklamani, MD, DSc

    Professor of Medicine, Division of Hematology/Oncology

    Virginia Kaklamani, MD, DSc is Professor of Medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center in San Antonio and is the Leader of the Breast Cancer Program at the Mays Cancer Center. She completed her fellowship in hematology/oncology at Northwestern University. She was Head of the Translational Breast Cancer Program at Northwestern University and co-director of the cancer genetics program at the same institution. Dr Kaklamani has also served as the Associate Director for Clinical Research at UT Health San Antonio. Her research interests include designing clinical trials with targeted agents. Dr Kaklamani has also identified several genetic mutations that link obesity and breast cancer.
  • Sara Tolaney, MD, MPH

    Sara Tolaney, MD, MPH

    Sara Tolaney, MD, MPH

    Associate Professor of Medicine

    Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute (Boston, MA). She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Dr. Tolaney received her medical degree from UC San Francisco. She completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Dr. Tolaney is the author of over 150 peer-reviewed publications.

CME Information

Global Logo PQH Logo

Looking Ahead Toward Better Outcomes for Heavily
Pre-Treated HR+/HER2- Metastatic Breast Cancer

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the National Breast Cancer Foundation.


This activity is supported by an educational grant from Gilead Sciences, Inc.


Monday, April 3, 2023 from 3:00-4:00pm ET


The primary target audience for this activity are breast oncologists and medical oncologists. The secondary audience for this activity are oncology pharmacists, oncology nurses, and oncology NPs/PAs.


Patients with HR+/HER2‐ metastatic breast cancer (MBC) are at increased risk of progression and adverse outcomes. While endocrine therapies are effective in early‐stage disease, patients with cancer that progresses to endocrine‐resistant disease have limited treatment options. Treatment can involve multiple chemotherapy regimens with high toxicity. However, additional therapeutic options are emerging for patients with HR+/HER2‐ MBC that has been heavily pretreated.

Join a panel of expert oncologists to discuss best practices for addressing treatment challenges for patients with heavily pretreated HR+/HER2‐ MBC. Panelists will share strategies for sequencing therapies in these patients and optimizing treatment in various patient subgroups. Recent data on emerging therapeutic options in this difficult‐to‐treat population will be reviewed, including novel antibody-drug conjugates (ADC) that have demonstrated efficacy in this population with reduced toxicity compared to chemotherapy.


After completing this activity, the participant should be better able to:
  • Discuss available therapies for HR+/HER2- metastatic breast cancer, as well as the need for additional options for patients who progress despite previous treatment
  • Apply evidence-based approaches for sequencing therapy in patients with HR+/HER2- metastatic breast cancer to maximize benefit and minimize toxicity
  • Evaluate data for emerging agents that can have a clinically significant benefit for subgroups of patients with HR+/HER2- metastatic breast cancer, such as those with endocrine-resistant disease



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Conflicts of Interest
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
Mays Cancer Center
UT Health San Antonio, MD Anderson Cancer Center
Consultant, Advisor, Speaker: AstraZeneca, Daichi Sankyo, Genentech, Gilead, Lilly, Menarini, Pfizer, Seagen
Sara Tolaney, MD, MPH
Chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers
Associate Director, Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Advisory Board: 4D Pharm, ARC Therapeutics, Artios , iopharmaceuticals, BeyondSpring Pharmaceuticals, Incyte Corp, Myovant, Reveal Genomics, Umoja Biopharma, Zentalis, Zymeworks
Consultant: Aadi Bio, Blueprint Medicines, CytomX, Daiichi Sankyo
Consultant/Advisory Board: Menarini/Stemline
Steering Committee: OncXerna
Principle Investigator of Study: Cyclacel, Exelixis, Nanostring, Nektar
Principle Investigator of Study/Consultant/Advisory Board: AstraZeneca, Bristol-Myers Squibb, Eisai, Genentech/Roche, Gilead, Merck, Novartis, Pfizer, Seattle Genetics
Principle Investigator of Study/Consultant/Advisory Board/Steering Committee: Eli Lilly

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For additional information about the accreditation of this activity, please visit

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at